Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 7.00 |
Expiry date | 2025-01-17 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
SOUTH SAN FRANCISCO, Calif., June 27, 2024--Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace. Vistagen’s supportiv
Vistagen Therapeutics ( NASDAQ:VTGN ) Full Year 2024 Results Key Financial Results Net loss: US$29.4m (loss narrowed by...
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript June 11, 2024 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. […]